Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Assessment of EBV DNA methlyation to guide antiviral use in EBV-associated lymphoma

Cara Noel, Christoph Weigel, Haley Klimaszewski et al. Nov 03, 2025 pp. 1752-1752 10.1182/blood-2025-1752

Abstract Intro/Objective: Epstein-Barr Virus (EBV), an oncogenic herpesvirus, can drive human lymphoma development. EBV uses DNA methylation...

HMGA1 chromatin regulators drive transcriptional networks governing cell cycle progression, immune escape, and menin-inhibitor resistance in KMT2A-r Acute Myeloid Leukemia

Bailey West, Li Luo, Zanshé Thompson et al. Nov 03, 2025 pp. 5027-5027 10.1182/blood-2025-5027

Abstract Introduction: KMT2A-rearranged acute myeloid leukemias (KMT2A-r AML) are highly lethal leukemias caused by rearrangements of the KM...

Successful surgical management in severe hemophilia A patients using efanesoctocog alfa: A two-case experience undergoing orthopedic surgery

Francisco-Jose Lopez-Jaime, Patricia Tejuca-Gonzalez, Antonio-Jose Roberto-Bernal et al. Nov 03, 2025 pp. 6625-6625 10.1182/blood-2025-6625

Abstract Introduction: Efanesoctocog alfa (Altuviiio®/Altuvoct®) is a newly approved, high-sustained recombinant factor VIII (rFVIII) with u...

Homoharringtonine added to CLAG regimen improves outcome of pediatric Relapsed/Refractory AML: A multicenter prospective study

Min Ruan, Shiyuan Wang, Jie Yu et al. Nov 03, 2025 pp. 5219-5219 10.1182/blood-2025-5219

Abstract Induction The prognosis of refractory/relapsed (R/R) Acute myeloid leukemia (AML) is dismal. Regimens including cladribine, cytarab...

Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium

Thai Hoa Tran, Meenakshi Devidas, Leyna Xoi et al. Nov 03, 2025 pp. 761-761 10.1182/blood-2025-761

Abstract Introduction: ABL-class acute lymphoblastic leukemia (ALL) is characterized by rearrangements of ABL1 or other...

The laminin receptor integrin α7β1 marks a highly migratory cell population and correlates with poor prognosis in Acute Myeloid Leukemia.

Saskia Rudat, Elsa Görsch, Marlon Arnone et al. Nov 03, 2025 pp. 3491-3491 10.1182/blood-2025-3491

Abstract Introduction: Interactions with the bone marrow (BM) niche are crucial for self-renewal and survival of acute myeloid leukemia (AML)...

National trends and demographic disparities in perinatal non-traumatic intracranial hemorrhage mortality in the United States, 1999–2024

Ibrahim Hassan, Alaa Mahmoud, Mennatullah A. Shehab et al. Nov 03, 2025 pp. 4475-4475 10.1182/blood-2025-4475

Abstract Background Non-traumatic intracranial hemorrhage (ICH) during the perinatal period is associated with substanti...

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Rong Wang, Jessica Stempel, Rory Shallis et al. Nov 03, 2025 pp. 6393-6393 10.1182/blood-2025-6393

Abstract RW, JMS co-first authors; XM, NP co-senior authors Background The first-generation TKI imatinib (IMA) is the mo...

Late onset and long lasting neutropenia & primary immune-dysregulation : Early signals & genetic connections

Maria Carla Giarratana, Paola Terranova, Marina Lanciotti et al. Nov 03, 2025 pp. 1203-1203 10.1182/blood-2025-1203

Abstract Background. Children affected with neutropenia that appears after age 5 years (Late Onset neutropenia, LO-Np) or lasts longer than...

Risk factors associated with intraparenchymal hemorrhage in patients with acute leukemia

John Cook, Kathryn Allen, Ximena Jordan Bruno Nov 03, 2025 pp. 5187-5187 10.1182/blood-2025-5187

Abstract Background: Intraparenchymal hemorrhage (IPH) is one of the most morbid complications of patients presenting with acute leukemia 1-...

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

William Wierda, Jennifer Brown, Paolo Ghia et al. Nov 03, 2025 pp. 2115-2115 10.1182/blood-2025-2115

Abstract Background: Covalent Bruton tyrosine kinase inhibitors (cBTKi) have dramatically changed the treatment (tx) landscape of chronic ly...

Utilization and outcomes of inferior vena cava (IVC) filters in patients with cancer-associated acute venous thromboembolism hospitalizations: Insights from the u.S. national inpatient sample 2018–2022

Fady El Tom, Raj Shah, Jad Kassem et al. Nov 03, 2025 pp. 3140-3140 10.1182/blood-2025-3140

Abstract BACKGROUND AND OBJECTIVE Cancer patients with acute venous thromboembolism (VTE) have complex management needs, and the use of infer...

Macrophage subsets provide distinct niches for normal and clonal hematopoiesis

Yirong Zhang, Zixuan Xu, Kun Wang et al. Nov 03, 2025 pp. 1402-1402 10.1182/blood-2025-1402

Abstract Hematopoietic stem cells (HSCs) are tightly regulated by the bone marrow (BM) niche to ensure blood homeostasis. Dysfunction of the...

Blood board: A virtual forum for classical hematology education and care improvement

Richard Godby, Xavier Andrade-Gonzalez, Emma St Martin et al. Nov 03, 2025 pp. 6420-6420 10.1182/blood-2025-6420

Abstract Introduction: The landscape of classical hematology has undergone substantial evolution over the last decade, marked by new diagnos...

Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab

Yi Xu, Chengyang Xu, Ai Guan et al. Nov 03, 2025 pp. 2190-2190 10.1182/blood-2025-2190

Abstract Systemic light-chain (AL) amyloidosis is a rare disorder characterized by deposition of misfolded monoclonal immunoglobulin light c...

Determining the origin of TP53 mutations in patients with mature B-cell neoplasms is essential to distinguish lymphoma-related mutations from those due to clonal hematopoiesis, helping to guide treatment decisions

Veronika Ecker, Wencke Walter, Martha-Lena Mueller et al. Nov 03, 2025 pp. 5389-5389 10.1182/blood-2025-5389

Abstract Background: Mutations (mut) in the TP53 gene are found in distinct mature B-cell neoplasms (B-NHL) and are frequently associated wi...

Molecular risk stratification and MRD-guided consolidation determine outcomes in pediatric non-down syndrome acute megakaryoblastic leukemia: A multicentre Chinese cohort study

Yongzhi Zheng, Chunxia Cai, Yiqiao Chen et al. Nov 03, 2025 pp. 5291-5291 10.1182/blood-2025-5291

Abstract Background: Management of pediatric acute megakaryoblastic leukemia (AMKL) without Down syndrome (non-DS-AMKL) remains challenging...

Hairy cell leukemia treatment strategies: A real-world multicenter experience

James Fradin, Lisa Rein, Anikó Szabó et al. Nov 03, 2025 pp. 1802-1802 10.1182/blood-2025-1802

Abstract Background Hairy cell leukemia (HCL) is a rare, indolent B-cell malignancy accounting for ~1% of all lymphoid n...

Prophylactic rituximab administered on day -1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients

Senlin Zhang, Qi Ji, Qingwei Wang et al. Nov 03, 2025 pp. 5988-5988 10.1182/blood-2025-5988

Abstract Background: Epstein–Barr virus (EBV) reactivation is a common and serious complication after pediatric allogeneic hematopoietic ste...

Epidemiology of cancer-associated bleeding in a nationwide electronic health record database

Ming Lim, Radhika Gangaraju, Omid Jafari et al. Nov 03, 2025 pp. 703-703 10.1182/blood-2025-703

Abstract Background People with cancer frequently experience hemostatic imbalances that result in excessive clotting or bleeding. While the...

Bioequivalence of ruxolitinib once-daily extended-release vs twice-daily immediate-release tablets in healthy adults

Xiaohua Gong, Zhiyin Xun, Jay Getsy et al. Nov 03, 2025 pp. 5045-5045 10.1182/blood-2025-5045

Abstract Background: Ruxolitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of adults with intermediate/high-r...

TCF-1 overexpression enhances CD19.CAR-T cell potency by attenuating activation-induced cell death

Qian Chen, Hao Yao, Xiyue Xu et al. Nov 03, 2025 pp. 4126-4126 10.1182/blood-2025-4126

Abstract Background The chimeric antigen receptor T cell targeting CD19 (CD19.CAR-T) has demonstrated encouraging therapeutic efficacy in tr...

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Katarina Micin, Ellen Madarang, Tiffany Nong et al. Nov 03, 2025 pp. 280-280 10.1182/blood-2025-280

Abstract In this study, we aimed to analyze the prognostic potential of a single-cell MRD (scMRD) assay in a prospective cohort of real worl...

Unannotated open reading frames expand the antigen repertoire in T cell acute lymphoblastic leukemia

Gbolahan Bamgbose, Caroline Wiggers, Burak Yuzuguldu et al. Nov 03, 2025 pp. 5147-5147 10.1182/blood-2025-5147

Abstract Background: T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy in which immature T cells clonall...

Elevated d-dimer predicts worse outcomes in hospitalized adults with sickle cell crisis: A real-world multicenter study

Divya Samat, Shivam Singh, Anish Sharda Nov 03, 2025 pp. 4748-4748 10.1182/blood-2025-4748

Abstract Background: Sickle cell disease (SCD) is marked by recurrent vaso-occlusive crises, which account for the major...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page